Work with LifeSpan to design a custom immunohistochemistry to address your specific biological question. Outsource the entire localization process without having to
worry about finding and characterizing target specific antibodies, sourcing and validating difficult-to-find tissues, and having the ability to interpret the resulting
immunostaining in relation to complex human pathologies.
TCR Screening Services
Test your therapeutic antibodies in immunohistochemistry against a broad panel of normal frozen human tissue types in order to determine potential unintended binding.
Our non-GLP TCR services are designed on the FDA recommendation outlined in their "Points to Consider in the Manufacture and Testing of Monoclonal Antibody Products for Human Use".
The receptor-binding domain of human FLT3L is fused at the N-terminus to the Fc portion of human IgG1.
Human IgG1 Fc
Greater than 95% by SDS-PAGE
In vitro and in vivo generation of conventional and plasmacytoid dendritic cells (DC). FLT3L increases in vivo both NK and DC cells numbers in the spleen when mice are injected intraperitoneally with 2 or 10 µg, daily for 10 days (slightly higher effect at 10 µg).
Less than 0.1 EU/µg protein (determined by LAL method).
Store at +4°C for immediate use, or aliquot and store at -20°C for at least 6 months. Avoid repeat freeze-thaw cycles.
Dendritic cells (DCs) provide the key link between innate and adaptive immunity by recognizing pathogens and priming pathogen-specific immune responses. FLT3LG controls the development of DCs and is particularly important for plasmacytoid DCs and CD8 (see MIM 186910)-positive classical DCs and their CD103 (ITGAE; MIM 604682)-positive tissue counterparts (summary by Sathaliyawala et al., 2010 [PubMed 20933441]).
Influence of FLT3L treatment on lymphocyte subpopulations. Method: C57BL/6 mice were injected intraperitoneally with 10 ug daily or were left untreated. (A) Percentages of indicated splenic subpopulations in FLT3L KO, WT control or WT-treated mice. (B) Absolute cell numbers of indicated splenic subpopulations in FLT3L KO, WT control, or WT-treated mice.
Requested From: United States
Date Requested: 2/25/2017